Bio Finance 2010 The who what where when and why?

BioFinance 2010 is the leading investor conference in Canada
for the life sciences industry. This three-day event brings together key
industry players interested in investment opportunities and issues affecting
companies in the life sciences sector. Presenting companies will span a range of
industries including: biologics, medical devices, drug delivery, vaccines,
diagnostics, bio-energy, green technologies, bio materials, industrial biotech,
and research services.

BioFinance 2010 will be held on April 6-7, 2010 at
the Toronto Marriott Eaton Centre. It begins with a gala Opening Reception on
April 6 and concludes with Sponsors Receptions on April 7.

In addition
to the BioFinance program, Sponsors will also be hosting individual events on
Tuesday April 6 and Thursday April 8. The details and location are currently
being developed. Please visit our website again for updates.

www.biofinance.ca/program

BioFinance with Gowling Lafleur Henderson Apr.6-8

Bio Finance with Gowling Lafleur Henderson Apr.6-8

This week’s BioFinance 2010 conference in Toronto brings light to a sector that has experienced significant challenges in 2009. With the biotechnology outlook dim, many companies were the targets of mergers and acquisitions. Part of the sector’s performance in 2009 can also be attributed to uncertainty about health care reform legislation in the United States. Given recent developments and the likelihood of a shake up within the sector, will biotechnology and medical technology be in demand for Canadian investors?

This week’s BioFinance 2010 conference in Toronto brings light to a sector that has experienced significant challenges in 2009. With the biotechnology outlook dim, many companies were the targets of mergers and acquisitions. Part of the sector’s performance in 2009 can also be attributed to uncertainty about health care reform legislation in the United States. Given recent developments and the likelihood of a shake up within the sector, will biotechnology and medical technology be in demand for Canadian investors?

Investors, analysts and legal professionals are looking towards next week’s conference for guidance on how this sector fairs for the remainder of 2010 and beyond. This industry may be positioned for renewed investor interest in 2010, despite the market lagging in 2009.

Gowling Lafleur Henderson (Gowlings) was recently named one of the world’s life science patent litigation law firms. I would be happy to set up an opportunity for you to speak with Michael Herman and Bob Ford, partners in Gowlings’ business law department, who are available during and after this conference to discuss how Canadians should view the biotechnology industry in 2010 and how they see the next generation of medicine development in Canada. Both professionals work to service the particular needs of technology and life sciences companies and those investors that fund them. Please let me know if you would like to discuss this opportunity.